Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012

2012-10-04 - 08:30

Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.

In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website. The company description (in Swedish) is also available at Vitrolife’s webpage www.vitrolife.com/corporate.

October 4, 2012

VITROLIFE AB (publ)

Thomas Axelsson

CEO


Queries should be addressed to:

Thomas Axelsson, CEO, phone 46 31 721 80 01

Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 4, 2012 at 08.30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.